

Diffuse Large B-cell Lymphoma (DLBCL) – Pipeline Insight, 2020

<https://marketpublishers.com/r/D39E25148E7DEN.html>

Date: September 2020

Pages: 112

Price: US\$ 2,500.00 (Single User License)

ID: D39E25148E7DEN

Abstracts

This report can be delivered to the clients within 96 Hours

DelveInsight's, "Diffuse Large B-cell Lymphoma (DLBCL) – Pipeline Insight, 2020," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Diffuse Large B-cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Diffuse Large B-cell Lymphoma Understanding

Diffuse Large B-cell Lymphoma (DLBCL): Overview

Lymphoma is a type of blood cancer that develops when white blood cells called lymphocytes grow out of control. Lymphocytes are part of your immune system. They travel around your body in your lymphatic system, helping you fight infections. There are two types of lymphocyte: T lymphocytes (T cells) and B lymphocytes (B cells). There are lots of different types of lymphoma. Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). It is a fast-growing (high-grade) lymphoma. Diffuse Large B-cell Lymphoma is an aggressive (fast-growing) NHL that affects B-lymphocytes. Lymphocytes are one type of white blood cell. B-cells are

lymphocytes that make antibodies to fight infections and are an important part of the lymphatic system.

Symptoms

Most people with Diffuse Large B-cell Lymphoma first notice painless lumps, often in their neck, armpit or groin. These are swollen (enlarged) lymph nodes. They usually grow quite quickly, over just a few weeks. Sometimes, Diffuse Large B-cell Lymphoma can develop in lymph nodes deep inside body where they can't be felt from the outside.

The exact symptoms depend on where in body the Diffuse Large B-cell Lymphoma is. These are called local symptoms. They can be very variable depending on what organs or tissues are affected. For example:

Diffuse Large B-cell Lymphoma in stomach or bowel can cause tummy (abdominal) discomfort or pain, diarrhoea or bleeding. Diffuse Large B-cell Lymphoma in chest can cause a cough or breathlessness.

Diagnosis

The main way to diagnose Diffuse Large B-cell Lymphoma is to remove a swollen lymph node, or a sample of cells from it, and look at it under a microscope. This involves a small operation called a biopsy, which is usually done under a local anaesthetic. The sample is also tested for particular proteins that are found on the surface of lymphoma cells. This can help medical team decide on the most appropriate treatment for you. There are other tests to find out which areas of body are affected by lymphoma. This is called staging. Staging usually involves having a PET scan and a CT scan. Some people, particularly children, may have an MRI scan.

Treatment

The treatments commonly used on Diffuse Large B-cell Lymphoma are chemotherapy drugs, radiation treatments, or immunotherapy. Doctors may also prescribe a combination of the three treatments. The most common chemotherapy treatment is referred to as R-CHOP. R-CHOP stands for a combination of the chemotherapy and immunotherapy medications rituximab, cyclophosphamide, doxorubicin, and vincristine, along with prednisone. R-CHOP is given through an IV for four of the medications, and prednisone is taken by mouth. R-CHOP is usually administered every three weeks.

Diffuse Large B-cell Lymphoma Emerging Drugs Chapters

This segment of the Diffuse Large B-cell Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diffuse Large B-cell Lymphoma Emerging Drugs

YY-20394: Shanghai YingLi Pharmaceutical Co. Ltd.

YY-20394 is an orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration, PI3K-delta inhibitor YY-20394 selectively binds to and inhibits PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.

Mosunetuzumab- Hoffmann-La Roche

Mosunetuzumab is a bispecific, humanized monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 bispecific monoclonal antibody BTCT4465A contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, BTCT4465A binds to both T cells and CD20-expressing tumor B cells; this cross-links T cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B cells.

Further product details are provided in the report

Diffuse Large B-cell Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Diffuse Large B-cell Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Diffuse Large B-cell Lymphoma

There are approx. 50+ key companies which are developing the therapies for Diffuse Large B-cell Lymphoma. The companies which have their Diffuse Large B-cell Lymphoma drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, MorphoSys, Kite, A Gilead Company, Karyopharm Therapeutics Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. etc.

Phases

DelveInsight's report covers around 50+ products under different phases of clinical development like

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Diffuse Large B-cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intramuscular

Intratumoral

Intravenous

Oral

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Gene therapies

CAR-T Therapies

Immunotherapies

Vaccines

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diffuse Large B-cell Lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diffuse Large B-cell Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diffuse Large B-cell Lymphoma drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Diffuse Large B-cell Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Diffuse Large B-cell Lymphoma.

August 2020: Selpercatinib had durable efficacy, including intracranial activity, with mainly low-grade toxic effects in patients with RET fusion–positive Diffuse Large B-cell Lymphoma who had previously received platinum-based chemotherapy and those who were previously untreated.

Diffuse Large B-cell Lymphoma Report Insights

Diffuse Large B-cell Lymphoma Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Diffuse Large B-cell Lymphoma Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Diffuse Large B-cell Lymphoma drugs?

How many Diffuse Large B-cell Lymphoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diffuse Large B-cell Lymphoma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diffuse Large B-cell Lymphoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Diffuse Large B-cell Lymphoma and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

MorphoSys

Kite

A Gilead Company

Karyopharm Therapeutics Inc.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Incyte Corporation

BeiGene

Autolus Limited

Hoffmann-La Roche

ADC Therapeutics S.A

Xynomic Pharmaceuticals, Inc.

Antengene Corporation

Acerta Pharma BV

Denovo Biopharma LLC

Key Products

KTE-C19

YY-20394

L19-IL2 - Ph I

TQB2303

INCB053914

BGB-3111

AUTO3

M7583

MOR00208

AMG 562

Mocetinostat

Contents

- Introduction
- Executive Summary
- Diffuse Large B-cell Lymphoma: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Diffuse Large B-cell Lymphoma – DelveInsight's Analytical Perspective
- In-depth Commercial Assessment
 - Diffuse Large B-cell Lymphoma companies' collaborations, Licensing, Acquisition -Deal Value Trends
- Diffuse Large B-cell Lymphoma Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Pre-registration)
 - Comparative Analysis
- Loncastuximab tesirine: ADC Therapeutics
 - Product Description
 - Research and Development
 - Product Development Activities
- Late Stage Products (Phase III)
 - Comparative Analysis
- TQB2303: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Abexinostat: Xynomic Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Early Stage Products (Phase I)

Comparative Analysis

Linperlisib: Shanghai Yingli Pharmaceutical

Product Description

Research and Development

Product Development Activities

INCB053914: Incyte Corporation

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....**Pre-clinical and Discovery Stage Products**

Comparative Analysis

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....**Inactive Products**

Comparative Analysis

Diffuse Large B-cell Lymphoma Key Companies**Diffuse Large B-cell Lymphoma Key Products****Diffuse Large B-cell Lymphoma- Unmet Needs****Diffuse Large B-cell Lymphoma- Market Drivers and Barriers****Diffuse Large B-cell Lymphoma- Future Perspectives and Conclusion****Diffuse Large B-cell Lymphoma Analyst Views****Diffuse Large B-cell Lymphoma Key Companies****Appendix**

List Of Tables

LIST OF TABLES

Table 1 Total Products for Diffuse Large B-cell Lymphoma

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Diffuse Large B-cell Lymphoma

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Diffuse Large B-cell Lymphoma (DLBCL) – Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/D39E25148E7DEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D39E25148E7DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970